Cited by 264Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisTransplantation: Methods and OutcomesPulmonary Hypertension Research and Treatments

An ex vivo model to induce early fibrosis-like changes in human precision-cut lung slices

Open access
Alsafadi, Hani N., Staab-Weijnitz, Claudia A., Lehmann, Mareike, Lindner, Michael, Peschel, Britta, Königshoff, Melanie, Wagner, Darcy E.·2017·American Journal of Physiology-Lung Cellular and Molecular Physiology

Abstract

Idiopathic pulmonary fibrosis (IPF) is a devastating chronic interstitial lung disease (ILD) characterized by lung tissue scarring and high morbidity. Lung epithelial injury, myofibroblast activation, and deranged repair are believed to be key processes involved in disease onset and progression, but the exact molecular mechanisms behind IPF remain unclear. Several drugs have been shown to slow disease progression, but treatments that halt or reverse IPF progression have not been identified. Ex vivo models of human lung have been proposed for drug discovery, one of which is precision-cut lung slices (PCLS). Although PCLS production from IPF explants is possible, IPF explants are rare and typically represent end-stage disease. Here we present a novel model of early fibrosis-like changes in human PCLS derived from patients without ILD/IPF using a combination of profibrotic growth factors and signaling molecules (transforming growth factor-β, tumor necrosis factor-α, platelet-derived growth factor-AB, and lysophosphatidic acid). Fibrotic-like changes of PCLS were qualitatively analyzed by histology and immunofluorescence and quantitatively by water-soluble tetrazolium-1, RT-qPCR, Western blot analysis, and ELISA. PCLS remained viable after 5 days of treatment, and fibrotic gene expression ( FN1, SERPINE1, COL1A1, CTGF, MMP7, and ACTA2) increased as early as 24 h of treatment, with increases in protein levels at 48 h and increased deposition of extracellular matrix. Alveolar epithelium reprogramming was evident by decreases in surfactant protein C and loss of HOPX. In summary, using human-derived PCLS, we established a novel ex vivo model that displays characteristics of early fibrosis and could be used to evaluate novel therapies and study early-stage IPF pathomechanisms.

Integrity signals

Registry

Crossref · 10.1152/ajplung.00084.2017

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • It is now possible to induce several features mimicking the fibrogenic response by applying a profibrotic cytokine cocktail (e.g. TGFβ1, LPA, and IL-1) in PCLS obtained from control tissue over the course of a few days.

    “it is now possible to induce several features which mimic the fibrogenic response by applying a profibrotic cytokine cocktail (e.g. TGFβ1, lysophosphatidic acid receptor (LPA), and interleukin-1 (IL-1)), in PCLS obtained from control tissue over the course of a few days (Alsafadi et al., 2017).”

    From Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies (2023) · cites this paper as Alsafadi et al., 2017

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Alsafadi, H. N., Staab-Weijnitz, C. A., Lehmann, M., Lindner, M., Peschel, B., Königshoff, M., & Wagner, D. E.
Affiliations
  • Helmholtz Munich (DE)
  • Asklepios Fachkliniken München-Gauting (DE)
  • Helmholtz Zentrum Munich, Comprehensive Pneumology Center, Member of the German Center for Lung Research, Munich, Germany;
Corresponding author
Wagner, Darcy E.
Venue
American Journal of Physiology-Lung Cellular and Molecular Physiology
Published
2017-06-01
Volume
312
Issue
6
Pages
L896-L902
ISSN
  • 1040-0605 (ISSN-L)
  • 1522-1504
OpenAlex
W2595866898
Cited by
263
References
21
Citations by year
2026: 25 · 2025: 52 · 2024: 39 · 2023: 41 · 2022: 25 · 2021: 24 · 2020: 19 · 2019: 21 · 2018: 14 · 2017: 3
FWCI
12.79
Type
journal article
Language
en
Licence
other-oa
Locations
  • American Journal of Physiology-Lung Cellular and Molecular Physiology (publishedVersion)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
  • Site cant be reached (submittedVersion, other-oa)
Funders
  • American Thoracic Society (ATS)
  • Helmholtz Zentrum München GmbH
  • Whitaker International Fellows and Scholars Program
  • Helmholtz Association
  • EC | European Research Council (ERC) (ERC-2010-StG 261302)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
idiopathic pulmonary fibrosis, precision-cut lung slices, ex vivo model, fibrosis, TGF-beta, TNF-α, PDGF-AB, lysophosphatidic acid, myofibroblast activation, extracellular matrix deposition, surfactant protein C, HOPX, interstitial lung disease
MeSH terms
Aged, Extracellular Matrix, Female, Humans, Lung, Male, Models, Biological, Tissue Survival, Biomarkers, Up-Regulation, Inflammation Mediators, Collagen Type I, Idiopathic Pulmonary Fibrosis, Alveolar Epithelial Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review